IL137353A0 - New salt forms of (2e) -5- amino-5-methylhex -2- enoic acid n-methyl -n- ((1r) -1-(n-methyl -n- ((1r) -1-(methylcarbamoyl) -2- phenylethyl) carbamoyl)-2-(2-naphthyl)ethyl)amid - Google Patents
New salt forms of (2e) -5- amino-5-methylhex -2- enoic acid n-methyl -n- ((1r) -1-(n-methyl -n- ((1r) -1-(methylcarbamoyl) -2- phenylethyl) carbamoyl)-2-(2-naphthyl)ethyl)amidInfo
- Publication number
- IL137353A0 IL137353A0 IL13735399A IL13735399A IL137353A0 IL 137353 A0 IL137353 A0 IL 137353A0 IL 13735399 A IL13735399 A IL 13735399A IL 13735399 A IL13735399 A IL 13735399A IL 137353 A0 IL137353 A0 IL 137353A0
- Authority
- IL
- Israel
- Prior art keywords
- methyl
- methylcarbamoyl
- phenylethyl
- carbamoyl
- naphthyl
- Prior art date
Links
- 150000003839 salts Chemical group 0.000 title abstract 2
- BKMADDIPSQRZPU-ONEGZZNKSA-N (e)-5-amino-5-methylhex-2-enoic acid Chemical compound CC(C)(N)C\C=C\C(O)=O BKMADDIPSQRZPU-ONEGZZNKSA-N 0.000 title 1
- WURGZWOTGMLDJP-ZCYANPAGSA-N (e)-5-amino-n,5-dimethyl-n-[(2r)-1-[methyl-[(2r)-1-(methylamino)-1-oxo-3-phenylpropan-2-yl]amino]-3-naphthalen-2-yl-1-oxopropan-2-yl]hex-2-enamide Chemical compound C([C@H](C(=O)NC)N(C)C(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)N(C)C(=O)\C=C\CC(C)(C)N)C1=CC=CC=C1 WURGZWOTGMLDJP-ZCYANPAGSA-N 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/60—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Endocrinology (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DK28298 | 1998-03-03 | ||
| PCT/DK1999/000089 WO1999045029A1 (en) | 1998-03-03 | 1999-02-26 | New salt forms of (2e)- 5-amino-5- methylhex-2- enoic acid n-methyl-n-((1r)-1-(n- methyl-n-((1r)-1-(methylcarbamoyl)-2- phenylethyl)carbamoyl)-2- (2-naphtyl)ethyl)amide |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL137353A0 true IL137353A0 (en) | 2001-07-24 |
Family
ID=8091813
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL13735399A IL137353A0 (en) | 1998-03-03 | 1999-02-26 | New salt forms of (2e) -5- amino-5-methylhex -2- enoic acid n-methyl -n- ((1r) -1-(n-methyl -n- ((1r) -1-(methylcarbamoyl) -2- phenylethyl) carbamoyl)-2-(2-naphthyl)ethyl)amid |
Country Status (15)
| Country | Link |
|---|---|
| EP (1) | EP1060190B1 (xx) |
| JP (1) | JP2002505340A (xx) |
| KR (1) | KR20010041533A (xx) |
| CN (1) | CN1291994A (xx) |
| AT (1) | ATE254632T1 (xx) |
| AU (1) | AU3247899A (xx) |
| BR (1) | BR9908399A (xx) |
| CA (1) | CA2322051A1 (xx) |
| DE (1) | DE69912930D1 (xx) |
| HU (1) | HUP0100998A3 (xx) |
| IL (1) | IL137353A0 (xx) |
| PL (1) | PL342706A1 (xx) |
| TW (1) | TW538047B (xx) |
| WO (1) | WO1999045029A1 (xx) |
| ZA (1) | ZA991572B (xx) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1407779A1 (en) | 2002-10-10 | 2004-04-14 | Gastrotech A/S | Use of ghrelin for treating low body weight and body fat in gastrectomized individuals |
| US7476653B2 (en) | 2003-06-18 | 2009-01-13 | Tranzyme Pharma, Inc. | Macrocyclic modulators of the ghrelin receptor |
| AR059066A1 (es) | 2006-01-27 | 2008-03-12 | Amgen Inc | Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf) |
| CU23558A1 (es) | 2006-02-28 | 2010-07-20 | Ct Ingenieria Genetica Biotech | Compuestos análogos a los secretagogos peptidicos de la hormona de crecimiento |
| EP2118080B1 (en) | 2007-02-09 | 2016-08-31 | Ocera Therapeutics, Inc. | Macrocyclic ghrelin receptor modulators and methods of using the same |
| WO2011035250A1 (en) | 2009-09-21 | 2011-03-24 | Gilead Sciences, Inc. | Processes and intermediates for the preparation of 1'-substituted carba-nucleoside analogs |
| KR101995598B1 (ko) | 2010-07-19 | 2019-07-02 | 길리애드 사이언시즈, 인코포레이티드 | 부분입체 이성질성으로 순수한 포스포라미데이트 전구약물의 제조 방법 |
| PL2595980T3 (pl) | 2010-07-22 | 2015-03-31 | Gilead Sciences Inc | Sposoby i związki do leczenia infekcji wirusowych Paramyxoviridae |
| TWI687432B (zh) | 2014-10-29 | 2020-03-11 | 美商基利科學股份有限公司 | 絲狀病毒科病毒感染之治療 |
| EP3242934B1 (en) | 2015-01-08 | 2021-08-18 | The Board of Trustees of the Leland Stanford Junior University | Factors and cells that provide for induction of bone, bone marrow, and cartilage |
| ES2918585T3 (es) | 2015-09-16 | 2022-07-19 | Gilead Sciences Inc | Métodos para el tratamiento de infecciones por el virus Arenaviridae |
| EP3595672B1 (en) | 2017-03-14 | 2023-09-06 | Gilead Sciences, Inc. | Compounds for use in methods of treating feline coronavirus infections |
| ES2938859T3 (es) | 2017-05-01 | 2023-04-17 | Gilead Sciences Inc | Una forma cristalina de (S)-2-etilbutilo 2-(((S)-(((2R,3S,4R,5R)-5-(4-aminopirrolo[2,1-f][1,2,4]triazin-7-il)-5-ciano-3,4-dihidroxitetrahidrofuran-2-il)metoxi)(fenoxi)fosforil)amino)propanoato |
| EP3651734A1 (en) | 2017-07-11 | 2020-05-20 | Gilead Sciences, Inc. | Compositions comprising an rna polymerase inhibitor and cyclodextrin for treating viral infections |
| JP2023512656A (ja) | 2020-01-27 | 2023-03-28 | ギリアード サイエンシーズ， インコーポレイテッド | ＳＡＲＳ ＣｏＶ－２感染を治療するための方法 |
| TWI785528B (zh) | 2020-03-12 | 2022-12-01 | 美商基利科學股份有限公司 | 1’-氰基核苷之製備方法 |
| KR20220164784A (ko) | 2020-04-06 | 2022-12-13 | 길리애드 사이언시즈, 인코포레이티드 | 1'-시아노 치환된 카르바뉴클레오시드 유사체의 흡입 제형 |
| EP4157272A1 (en) | 2020-05-29 | 2023-04-05 | Gilead Sciences, Inc. | Remdesivir treatment methods |
| TWI819321B (zh) | 2020-06-24 | 2023-10-21 | 美商基利科學股份有限公司 | 1'-氰基核苷類似物及其用途 |
| TW202228722A (zh) | 2020-08-27 | 2022-08-01 | 美商基利科學股份有限公司 | 用於治療病毒感染之化合物及方法 |
| EP4320128A1 (en) | 2022-03-02 | 2024-02-14 | Gilead Sciences, Inc. | Compounds and methods for treatment of viral infections |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69637855D1 (de) * | 1995-12-22 | 2009-04-16 | Novo Nordisk As | Verbindungen mit wachstumshormon-freisetzenden eigenschaften |
-
1999
- 1999-02-26 HU HU0100998A patent/HUP0100998A3/hu unknown
- 1999-02-26 BR BR9908399-0A patent/BR9908399A/pt not_active IP Right Cessation
- 1999-02-26 AU AU32478/99A patent/AU3247899A/en not_active Abandoned
- 1999-02-26 PL PL99342706A patent/PL342706A1/xx not_active Application Discontinuation
- 1999-02-26 AT AT99937933T patent/ATE254632T1/de not_active IP Right Cessation
- 1999-02-26 WO PCT/DK1999/000089 patent/WO1999045029A1/en not_active Application Discontinuation
- 1999-02-26 CA CA002322051A patent/CA2322051A1/en not_active Abandoned
- 1999-02-26 EP EP99937933A patent/EP1060190B1/en not_active Expired - Lifetime
- 1999-02-26 JP JP2000534571A patent/JP2002505340A/ja active Pending
- 1999-02-26 KR KR1020007009706A patent/KR20010041533A/ko not_active Application Discontinuation
- 1999-02-26 CN CN99803429A patent/CN1291994A/zh active Pending
- 1999-02-26 DE DE69912930T patent/DE69912930D1/de not_active Expired - Lifetime
- 1999-02-26 IL IL13735399A patent/IL137353A0/xx unknown
- 1999-02-26 ZA ZA9901572A patent/ZA991572B/xx unknown
- 1999-03-30 TW TW088105002A patent/TW538047B/zh active
Also Published As
| Publication number | Publication date |
|---|---|
| WO1999045029A1 (en) | 1999-09-10 |
| HUP0100998A3 (en) | 2001-12-28 |
| EP1060190A1 (en) | 2000-12-20 |
| CN1291994A (zh) | 2001-04-18 |
| JP2002505340A (ja) | 2002-02-19 |
| DE69912930D1 (de) | 2003-12-24 |
| ZA991572B (en) | 1999-09-03 |
| HUP0100998A2 (hu) | 2001-08-28 |
| PL342706A1 (en) | 2001-07-02 |
| ATE254632T1 (de) | 2003-12-15 |
| CA2322051A1 (en) | 1999-09-10 |
| EP1060190B1 (en) | 2003-11-19 |
| AU3247899A (en) | 1999-09-20 |
| KR20010041533A (ko) | 2001-05-25 |
| BR9908399A (pt) | 2000-10-31 |
| TW538047B (en) | 2003-06-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL137353A0 (en) | New salt forms of (2e) -5- amino-5-methylhex -2- enoic acid n-methyl -n- ((1r) -1-(n-methyl -n- ((1r) -1-(methylcarbamoyl) -2- phenylethyl) carbamoyl)-2-(2-naphthyl)ethyl)amid | |
| RS82003A (xx) | Amidi antranilne kiseline, postupak za njihovu proizvodnju, njihova primena u svojstvu antiaritmijskih sredstava kao i farmaceutski preparati koji sadrže ta jedinjenja | |
| MY133647A (en) | Substituted quinoline-2-carboxamides, their preparation and their use as pharmaceuticals, and intermediates | |
| AU2003245804A1 (en) | Hazard-free microencapsulation for structurally delicate agents, an application of stable aqueous-aqueous emulsion | |
| MY142589A (en) | Benzimidazole derivatives : preparation and pharmaceutical applications | |
| EP1961748A3 (en) | 2-Hydroxy-3-heteroarylindole derivatives as GSK3 inhibitors | |
| WO2004043363A8 (en) | Protein-stabilized liposomal formulations of pharmaceutical agents | |
| IL145430A0 (en) | N-cyanomethyl amides, processes for the preparation thereof and pharmaceutical compositions containing the same | |
| SG169224A1 (en) | Method for treatment of tumors using nordihydrogualaretic acid derivatives | |
| MXPA02002249A (es) | Composiciones farmaceuticas agradables al paladar para animales de compania. | |
| HK1066539A1 (en) | Ortho-substituted nitrogen-containing bisaryl compounds use as potassium channel inhibitors | |
| IN2005KO00312A (xx) | ||
| NO20061575L (no) | Fremgangsmate for fremstilling av renzapride og mellomprodukter derav | |
| EP0981352B8 (en) | Use of aplidine for the treatment of cardiovascular diseases | |
| WO2002057215A3 (en) | Sodium channel modulators | |
| TW200420557A (en) | Salt of 7-isoindoline-quinolonecarboxylic acid derivative, its hydrate and anti-bacterially pharmaceutical composition comprising the same as active ingredient | |
| AU2001267886A1 (en) | Epoxycarboxylic acid amides, azides and amino alcohols and processes for preparation of alpha-keto amides by using them | |
| TW324662B (en) | Benzamide-containing pharmaceutical composition | |
| MXPA03009984A (es) | PREPARACION PARA LA REMOCIoN DE MATERIAL QUERATINOSO ANORMAL. | |
| BG104243A (en) | Method for the synthesis of quinoline derivatives | |
| AU2003267360A1 (en) | Hair treatment agent containing an active combination of liposomes | |
| WO2003017762A3 (de) | Fungizide wirkstoffkombinationen | |
| MXPA05008711A (es) | Uso de r-10-hidroxi-10,11-dihidro-carbamazepina en dolor neuropatico. | |
| MY122588A (en) | Crystalline forms of the sodium salt of 5-chloro-2-methoxy-n-(2-(4-methoxy-3-methylaminothiocarbonylaminosulfonylphenyl)ethyl)benzamide | |
| AU2003294834A1 (en) | Anthranilic acid amide derivatives and their pharmaceutical use |